MPP – Biovac, mRNA Vaccine Technology Transfer Agreement

Provision Language

RECITALS

WHEREAS, MPP, in collaboration with the World Health Organization (“WHO”), has established the mRNA Technology Transfer Programme with the aim to establish or enhance sustainable mRNA vaccines manufacturing capacity in low- and middle-income countries (“LMICs”), in particular to improve the ability of such countries to better respond to the COVID-19 pandemic and other future pandemics.